These data implied that the inhibitory effect of rosiglitazone on TGF-β1-stimulated ECM expression mainly operated through modulations of the SMAD pathway rather than the MAPK pathways in ADPKD cyst lining epithelial cells. This evidence concerns the gene TGFB1 and cyst.